[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2000021516A3 - Methods for inhibiting diabetic complications - Google Patents

Methods for inhibiting diabetic complications Download PDF

Info

Publication number
WO2000021516A3
WO2000021516A3 PCT/US1999/023869 US9923869W WO0021516A3 WO 2000021516 A3 WO2000021516 A3 WO 2000021516A3 US 9923869 W US9923869 W US 9923869W WO 0021516 A3 WO0021516 A3 WO 0021516A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diabetic complications
treat
instant invention
post
Prior art date
Application number
PCT/US1999/023869
Other languages
French (fr)
Other versions
WO2000021516A2 (en
Inventor
Raja Gabriel Khalifah
Billy G Hudson
Original Assignee
Kansas University Medical Ct R
Raja Gabriel Khalifah
Billy G Hudson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kansas University Medical Ct R, Raja Gabriel Khalifah, Billy G Hudson filed Critical Kansas University Medical Ct R
Priority to AU11125/00A priority Critical patent/AU1112500A/en
Publication of WO2000021516A2 publication Critical patent/WO2000021516A2/en
Publication of WO2000021516A3 publication Critical patent/WO2000021516A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-amadori AGE formation, and such identified inhibitor compositions. The instant invention also teaches new methods to treat or prevent diabetic nephropathy, oxidative stress, and protein crosslinking, comprising administering an amount effective of one of the compounds of the invention to treat or prevent the disorder.
PCT/US1999/023869 1998-10-14 1999-10-13 Methods for inhibiting diabetic complications WO2000021516A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU11125/00A AU1112500A (en) 1998-10-14 1999-10-13 Methods for inhibiting diabetic complications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10427698P 1998-10-14 1998-10-14
US60/104,276 1998-10-14

Publications (2)

Publication Number Publication Date
WO2000021516A2 WO2000021516A2 (en) 2000-04-20
WO2000021516A3 true WO2000021516A3 (en) 2001-01-04

Family

ID=22299580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023869 WO2000021516A2 (en) 1998-10-14 1999-10-13 Methods for inhibiting diabetic complications

Country Status (2)

Country Link
AU (1) AU1112500A (en)
WO (1) WO2000021516A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128295A1 (en) * 2000-11-02 2002-09-12 John Baynes Use of pyridoxamine for the treatment and inhibition of obesity-related complications
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
US8822542B2 (en) 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
EP2041114B1 (en) * 2006-07-07 2016-03-02 NephroGenex, Inc. Inhibitors of advanced glycation end products
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2013012715A1 (en) * 2011-07-15 2013-01-24 Vanderbilt University Methods for treating inflammation
BR112019022523A2 (en) * 2017-04-27 2020-05-12 Vanderbilt University METHODS FOR TREATING AEROSCLEROSIS WITH GETO-KETOALDEHYDE SEQUESTRANTS
CA3149383A1 (en) 2019-08-01 2021-02-04 Praetego, Inc. Inhibitors of advanced glycation end products

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2349330A1 (en) * 1976-04-29 1977-11-25 Savini Emile Compsns. contg. pyridoxine and an antioxidant esp. tocopherol - used for treatment of hyperlipidaemia
DE3542309A1 (en) * 1985-11-29 1987-06-04 Cardona Federico Dr Medicinal antioxidant
WO1992002216A1 (en) * 1990-08-01 1992-02-20 Univ Rockefeller Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
EP0474874A1 (en) * 1990-02-19 1992-03-18 Senju Pharmaceutical Co., Ltd. Maillard Reaction inhibitor compositions
WO1994000135A1 (en) * 1992-06-30 1994-01-06 Shapiro Howard K Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
WO1997009981A1 (en) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
JPH09221425A (en) * 1996-02-13 1997-08-26 Taiho Yakuhin Kogyo Kk Thiol protease inhibitor
JPH10158244A (en) * 1996-12-02 1998-06-16 Kissei Pharmaceut Co Ltd 5-aminoalkyl-4-aminomethyl-3-hydroxypyridine derivative and maillard reaction inhibitor containing the same
JPH10175954A (en) * 1996-12-12 1998-06-30 Kissei Pharmaceut Co Ltd 4-aminomethyl-3-hydroxypyridine derivative and maillard reaction inhibitor containing the same
WO1999025690A2 (en) * 1997-11-17 1999-05-27 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO2000022094A2 (en) * 1998-10-09 2000-04-20 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2349330A1 (en) * 1976-04-29 1977-11-25 Savini Emile Compsns. contg. pyridoxine and an antioxidant esp. tocopherol - used for treatment of hyperlipidaemia
DE3542309A1 (en) * 1985-11-29 1987-06-04 Cardona Federico Dr Medicinal antioxidant
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
EP0474874A1 (en) * 1990-02-19 1992-03-18 Senju Pharmaceutical Co., Ltd. Maillard Reaction inhibitor compositions
WO1992002216A1 (en) * 1990-08-01 1992-02-20 Univ Rockefeller Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
WO1994000135A1 (en) * 1992-06-30 1994-01-06 Shapiro Howard K Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
WO1997009981A1 (en) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
JPH09221425A (en) * 1996-02-13 1997-08-26 Taiho Yakuhin Kogyo Kk Thiol protease inhibitor
JPH10158244A (en) * 1996-12-02 1998-06-16 Kissei Pharmaceut Co Ltd 5-aminoalkyl-4-aminomethyl-3-hydroxypyridine derivative and maillard reaction inhibitor containing the same
JPH10175954A (en) * 1996-12-12 1998-06-30 Kissei Pharmaceut Co Ltd 4-aminomethyl-3-hydroxypyridine derivative and maillard reaction inhibitor containing the same
WO1999025690A2 (en) * 1997-11-17 1999-05-27 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO2000022094A2 (en) * 1998-10-09 2000-04-20 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"THE MECK MANUAL", 1987, MERCK SHARP & DOHME RESEARCH LABORATORIES, RAHWAY, N.J., XP002135612 *
BAYNES, J. W. ET AL: "Pyridorin, a post-Amadori inhibitor of advanced glycation reactions, preserves renal function in diabetic rats.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (SEPT., 1998) VOL. 9, NO. PROGRAM AND ABSTR. ISSUE, PP. 628A. MEETING INFO.: 31ST ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY PHILADELPHIA, PENNSYLVANIA, USA OCTOBER 25-28, 1998 AMERICAN SOCIETY, XP000901645 *
BOOTH A A ET AL: "IN VITRO KINETIC STUDIES OF FORMATION OF ANTIGENIC ADVANCED GLYCATION END PRODUCTS (AGES)", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 9, 28 February 1997 (1997-02-28), pages 5430 - 5437, XP002068236, ISSN: 0021-9258 *
BOOTH A A ET AL: "THIAMINE PYROPHOSPHATE AND PYRIDOXAMINE INHIBIT THE FORMATION OF ANTIGENIC ADVANCED GLYCATION END-PRODUCTS: COMPARISON WITH AMINOGUANIDINE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 220, no. 1, 1 January 1996 (1996-01-01), pages 113 - 119, XP002024845, ISSN: 0006-291X *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IYOBE, AKIRA ET AL: "4-aminomethyl-3-hydroxypyridines and Maillard reaction inhibitors containing them", XP002135574, retrieved from STN Database accession no. 129:131256 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IYOBE, AKIRA ET AL: "5-Aminoalkyl-4-aminomethyl-3-hydroxypyridines and Maillard reaction inhibitors containing them", XP002135575, retrieved from STN Database accession no. 129:104228 *
DATABASE WPI Section Ch Week 199748, Derwent World Patents Index; Class B03, AN 1997-516155, XP002148329 *
KHALIFAH R G (REPRINT) ET AL: "Effects of pyridoxamine, a novel post- Amadori AGE inhibitor, on nephropathy induced by glycated albumin.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (SEP 1997) VOL. 8, SUPP. [S], PP. A2988-A2988. PUBLISHER: WILLIAMS & WILKINS, 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436. ISSN: 1046-6673., UNIV KANSAS, MED CTR, SCH MED, KANSAS CITY, KS 66103;UNIV NIJMEGEN HOSP, DIV NEPHROL, NL-6500 HB NIJMEGEN, NETHERLANDS, XP000901589 *
KHALIFAH R G ET AL: "Amadorins: novel post- Amadori inhibitors of advanced glycation reactions.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1999 APR 13) 257 (2) 251-8. REF: 65, XP000891744 *
O. CHAPPEY ET AL.: "Advanced glycation end products, oxidant stress and vascular lesions", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 27, 1997, pages 97 - 108, XP000949250 *
S FU ET AL.: "Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins", BIOCHEMICAL JOURNAL, vol. 330, 1998, pages 233 - 239, XP000949249 *

Also Published As

Publication number Publication date
WO2000021516A2 (en) 2000-04-20
AU1112500A (en) 2000-05-01

Similar Documents

Publication Publication Date Title
WO1999025690A3 (en) Advanced glycation end-product intermediaries and post-amadori inhibition
WO2003049678A3 (en) Mitotic kinesin inhibitors
WO2003050064A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
EP0766676A4 (en) Compounds for and method of inhibiting phosphodiesterase iv
BR0116792A (en) Substituted triazole diamine derivatives as kinase inhibitors
WO2000035436A3 (en) Treatment of arthritis with mek inhibitors
WO2004007520A3 (en) Methods and compositions for preventing oxidative degradation of proteins
WO2007026251A8 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2000077206A3 (en) The myostatin gene promoter and inhibition of activation thereof
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
WO2000004954A3 (en) Novel urokinase inhibitors
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
WO1998036730A3 (en) Compositions for treating acne rosacea
WO2000021516A3 (en) Methods for inhibiting diabetic complications
WO2004032908A3 (en) Method of inhibiting angiogenesis
WO1997038966A3 (en) Cytoprotective compounds
EP1099442A3 (en) Methods of administering apo B-secretion/MTP inhibitors
WO2000023063A3 (en) Methods for inhibiting diabetic complications
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
WO2004060878A3 (en) Inhibitors of phosphatases

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 11125

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase